Wockhardt Limited
WOCKPHARMA
Hisse Senetlerindeki Sıralama
#4524
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Hisse Fiyatı
$21.04
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$3.42B
Değişim (1 gün)
-2.39%
Değişim (1 yıl)
34.90%
Ülke
IN
Ticaret Wockhardt Limited (WOCKPHARMA)
Kategori
Healthcare
Wockhardt Limited (WOCKPHARMA) için P/B oranı
October 2026 itibarıyla P/B oranı TTM: 6.02
Wockhardt Limited şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 6.02'dir. 2024 yılının sonunda şirketin P/B oranı 2.57 idi.
Wockhardt Limited için P/B oranı geçmişi 2004 - 2026 arası
Her yılın sonunda P/B oranı
| Yıl | P/B Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 6.02 | 16.16% |
| 2025 | 5.18 | 101.34% |
| 2024 | 2.57 | 288.97% |
| 2023 | 0.66 | -19.95% |
| 2022 | 0.83 | -43.97% |
| 2021 | 1.47 | 89.81% |
| 2020 | 0.78 | -61.99% |
| 2019 | 2.04 | -35.21% |
| 2018 | 3.15 | 21.94% |
| 2017 | 2.59 | -14.18% |
| 2016 | 3.01 | -49.76% |
| 2015 | 6.00 | 294.23% |
| 2014 | 1.52 | -82.90% |
| 2013 | 8.90 | 84.07% |
| 2012 | 4.83 | 41.70% |
| 2011 | 3.41 | 72.95% |
| 2010 | 1.97 | 55.55% |
| 2008 | 1.27 | -67.48% |
| 2007 | 3.90 | -0.89% |
| 2006 | 3.93 | -39.11% |
| 2005 | 6.46 | -5.15% |
| 2004 | 6.81 | 0.00% |
Benzer şirketler veya rakipler için P/B oranı
| Şirket | P/B Oranı | P/B Oranı Farkı | Ülke |
|---|---|---|---|
| 3.8424 | -36.14% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 17.3539 | 188.42% |
US
|
